SMT201900504T1 - Proteine di fusione tatk-cdkl5, composizioni, formulazioni e loro uso - Google Patents
Proteine di fusione tatk-cdkl5, composizioni, formulazioni e loro usoInfo
- Publication number
- SMT201900504T1 SMT201900504T1 SM20190504T SMT201900504T SMT201900504T1 SM T201900504 T1 SMT201900504 T1 SM T201900504T1 SM 20190504 T SM20190504 T SM 20190504T SM T201900504 T SMT201900504 T SM T201900504T SM T201900504 T1 SMT201900504 T1 SM T201900504T1
- Authority
- SM
- San Marino
- Prior art keywords
- tatk
- formulations
- compositions
- fusion proteins
- cdkl5 fusion
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 2
- 238000009472 formulation Methods 0.000 title 1
- 102000037865 fusion proteins Human genes 0.000 title 1
- 108020001507 fusion proteins Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4737—C-reactive protein
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C07K2319/41—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
- C12N2501/405—Cell cycle regulated proteins, e.g. cyclins, cyclin-dependant kinases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/11—Protein-serine/threonine kinases (2.7.11)
- C12Y207/11022—Cyclin-dependent kinase (2.7.11.22)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Marine Sciences & Fisheries (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461946280P | 2014-02-28 | 2014-02-28 | |
| EP15736034.8A EP3110837B1 (en) | 2014-02-28 | 2015-02-27 | Tatk-cdkl5 fusion proteins, compositions, formulations, and use thereof |
| PCT/IB2015/000999 WO2015128746A2 (en) | 2014-02-28 | 2015-02-27 | Tatk-cdkl5 fusion proteins, compositions, formulations, and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SMT201900504T1 true SMT201900504T1 (it) | 2019-11-13 |
Family
ID=53539745
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SM20190504T SMT201900504T1 (it) | 2014-02-28 | 2015-02-27 | Proteine di fusione tatk-cdkl5, composizioni, formulazioni e loro uso |
| SM20210478T SMT202100478T1 (it) | 2014-02-28 | 2015-02-27 | Proteine di fusione tatk-cdkl5, composizioni, formulazioni e loro uso |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SM20210478T SMT202100478T1 (it) | 2014-02-28 | 2015-02-27 | Proteine di fusione tatk-cdkl5, composizioni, formulazioni e loro uso |
Country Status (33)
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SMT201900504T1 (it) * | 2014-02-28 | 2019-11-13 | Univ Bologna Alma Mater Studiorum | Proteine di fusione tatk-cdkl5, composizioni, formulazioni e loro uso |
| US20210268072A1 (en) * | 2016-06-28 | 2021-09-02 | Alma Mater Studiorum - Universitá Di Bologna | TATk-CDKL5 Fusion Proteins, Compositions, Formulations, and Use Thereof |
| US20200299654A1 (en) * | 2017-11-30 | 2020-09-24 | Amicus Therapeutics, Inc. | Cdkl5 expression variants and cdkl5 fusion proteins |
| EP4028413A1 (en) | 2019-09-10 | 2022-07-20 | Obsidian Therapeutics, Inc. | Ca2-il15 fusion proteins for tunable regulation |
| EP4073231A4 (en) * | 2019-10-30 | 2024-06-05 | Amicus Therapeutics, Inc. | RECOMBINANT CDKL5 PROTEINS, GENE THERAPY AND METHODS OF PRODUCTION |
| IT202000025423A1 (it) * | 2020-10-27 | 2022-04-27 | Ulisse Biomed S P A | Uso di proteine per il trattamento di patologie associate a tossine formanti pori o a proteine virali |
| IL303239A (en) | 2020-12-01 | 2023-07-01 | Univ Pennsylvania | Compositions and their uses for the treatment of Engelmann syndrome |
| WO2025050032A1 (en) * | 2023-08-31 | 2025-03-06 | Ultragenyx Pharmaceutical Inc. | Methods of producing cdkl5 proteins and uses of the same |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2632444A1 (en) * | 2010-10-25 | 2013-09-04 | Université d'Aix-Marseille | TREATMENT OF MeCP2-ASSOCIATED DISORDERS |
| SMT201900504T1 (it) * | 2014-02-28 | 2019-11-13 | Univ Bologna Alma Mater Studiorum | Proteine di fusione tatk-cdkl5, composizioni, formulazioni e loro uso |
-
2015
- 2015-02-27 SM SM20190504T patent/SMT201900504T1/it unknown
- 2015-02-27 PT PT15736034T patent/PT3110837T/pt unknown
- 2015-02-27 SI SI201530884T patent/SI3110837T1/sl unknown
- 2015-02-27 SI SI201531680T patent/SI3608334T1/sl unknown
- 2015-02-27 HU HUE15736034A patent/HUE045393T2/hu unknown
- 2015-02-27 RS RSP20191144 patent/RS59344B1/sr unknown
- 2015-02-27 CA CA2940401A patent/CA2940401C/en active Active
- 2015-02-27 ES ES19179287T patent/ES2885245T3/es active Active
- 2015-02-27 SM SM20210478T patent/SMT202100478T1/it unknown
- 2015-02-27 EA EA201691691A patent/EA038000B1/ru unknown
- 2015-02-27 EP EP19179287.8A patent/EP3608334B1/en active Active
- 2015-02-27 DK DK19179287.8T patent/DK3608334T3/da active
- 2015-02-27 EP EP15736034.8A patent/EP3110837B1/en active Active
- 2015-02-27 HR HRP20191511 patent/HRP20191511T1/hr unknown
- 2015-02-27 DK DK15736034.8T patent/DK3110837T3/da active
- 2015-02-27 WO PCT/IB2015/000999 patent/WO2015128746A2/en not_active Ceased
- 2015-02-27 CN CN201580010858.9A patent/CN106255706A/zh active Pending
- 2015-02-27 ES ES15736034T patent/ES2745335T3/es active Active
- 2015-02-27 HU HUE19179287A patent/HUE055282T2/hu unknown
- 2015-02-27 US US14/633,757 patent/US9290746B2/en active Active
- 2015-02-27 MY MYPI2016001567A patent/MY181566A/en unknown
- 2015-02-27 PL PL15736034T patent/PL3110837T3/pl unknown
- 2015-02-27 MX MX2016011167A patent/MX2016011167A/es active IP Right Grant
- 2015-02-27 SG SG10202000537RA patent/SG10202000537RA/en unknown
- 2015-02-27 JP JP2016553630A patent/JP6629747B2/ja active Active
- 2015-02-27 CR CR20160392A patent/CR20160392A/es unknown
- 2015-02-27 EA EA202190727A patent/EA202190727A3/ru unknown
- 2015-02-27 PE PE2016001528A patent/PE20161406A1/es not_active Application Discontinuation
- 2015-02-27 AU AU2015221860A patent/AU2015221860B2/en active Active
- 2015-02-27 MX MX2020001223A patent/MX392778B/es unknown
- 2015-02-27 LT LTEP19179287.8T patent/LT3608334T/lt unknown
- 2015-02-27 LT LTEP15736034.8T patent/LT3110837T/lt unknown
- 2015-02-27 BR BR112016019868-9A patent/BR112016019868B1/pt not_active IP Right Cessation
- 2015-02-27 PL PL19179287T patent/PL3608334T3/pl unknown
- 2015-02-27 KR KR1020167026521A patent/KR102307276B1/ko active Active
- 2015-02-27 SG SG11201606863YA patent/SG11201606863YA/en unknown
- 2015-02-27 RS RS20211041A patent/RS62244B1/sr unknown
- 2015-02-27 PT PT191792878T patent/PT3608334T/pt unknown
-
2016
- 2016-03-21 US US15/075,457 patent/US9944910B2/en active Active
- 2016-08-23 DO DO2016000220A patent/DOP2016000220A/es unknown
- 2016-08-24 CL CL2016002142A patent/CL2016002142A1/es unknown
- 2016-08-25 PH PH12016501689A patent/PH12016501689B1/en unknown
- 2016-08-25 IL IL247481A patent/IL247481B/en active IP Right Grant
- 2016-08-26 NI NI201600127A patent/NI201600127A/es unknown
- 2016-08-26 SV SV2016005264A patent/SV2016005264A/es unknown
- 2016-09-26 ZA ZA2016/06655A patent/ZA201606655B/en unknown
-
2018
- 2018-04-16 US US15/954,021 patent/US10584318B2/en active Active
-
2019
- 2019-08-20 AU AU2019219743A patent/AU2019219743B2/en active Active
- 2019-09-11 CY CY20191100949T patent/CY1122644T1/el unknown
- 2019-09-25 ZA ZA2019/06304A patent/ZA201906304B/en unknown
- 2019-12-05 JP JP2019220178A patent/JP6896050B2/ja active Active
-
2020
- 2020-03-06 US US16/811,484 patent/US10907138B2/en active Active
- 2020-06-17 IL IL275435A patent/IL275435B/en unknown
-
2021
- 2021-08-17 HR HRP20211324TT patent/HRP20211324T1/hr unknown
- 2021-08-19 CY CY20211100743T patent/CY1124727T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL276695B (en) | Antibodies, pharmaceutical preparations and their uses | |
| IL257030A (en) | Multivalent and multispecific cleavage proteins that bind to gitr Preparations containing them and uses thereof | |
| ZA201707749B (en) | Compounds targeting proteins, compositions, methods, and uses thereof | |
| IL275435A (en) | TATK – CDKL5 fusion proteins, preparations, formulations, and their uses | |
| IL290114A (en) | Pharmaceutical preparations, their preparation and uses | |
| IL263842A (en) | Tatk -cdkl5 fusion proteins, compositions, formulations, and use thereof | |
| HUE056175T2 (hu) | Gyógyászati készítmények, elõállításuk és alkalmazásaik | |
| IL252397A0 (en) | Pharmaceutical preparations, their preparation and uses | |
| PL3229843T3 (pl) | Kompozycja farmaceutyczna, wytwarzanie i zastosowanie tej kompozycji | |
| HK1234652A1 (en) | Protein formulations |